PRODUCT OVERVIEW & COMPOSITION
Brand / Manufacturer: Bioniche Pharma
Active Ingredient: Sibutramine Hydrochloride Monohydrate (20 mg per tablet)
Pharmacological Class: Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) / Centrally Acting Appetite Suppressant
Bioniche Pharma Sibutramine Hydrochloride is an orally active centrally acting agent designed for the therapeutic management of exogenous obesity. It operates by inhibiting the reuptake of key neurotransmitters, thereby increasing satiety and enhancing basal metabolic rate.
PHYSICOCHEMICAL CHARACTERISTICS
Bioniche Pharma Sibutramine Hydrochloride Monohydrate appears as a white to cream crystalline powder. It demonstrates an aqueous solubility of 2.9 mg/mL in a buffered medium of pH 5.2 and possesses an octanol:water partition coefficient of 30.9 at pH 5.0, reflecting its lipophilic nature and favorable biological membrane permeability.
CLINICAL PHARMACOLOGY & DYNAMICS
Unlike classic amphetamine-based anorectics, Bioniche Pharma Sibutramine acts primarily via its active secondary and primary amine metabolites to selectively inhibit the neuronal reuptake of norepinephrine, serotonin ($5\text{-HT}$), and to a lesser extent, dopamine. This mechanism increases post-prandial satiety (reducing caloric intake) and prevents the decline in resting energy expenditure typically associated with dietary restriction.
INDICATIONS & CLINICAL USE
- Management of obesity in patients with an elevated initial Body Mass Index (BMI), including structured weight reduction and maintenance of weight loss under Bioniche Pharma treatment protocols.
- Adjunctive therapy administered in conjunction with a medically supervised, calorie-restricted dietary and behavioral modification program utilizing Bioniche Pharma products.
DOSAGE & ADMINISTRATION
Dosing protocols for Bioniche Pharma Sibutramine must be individualized and administered under strict medical supervision. Patient selection, baseline cardiovascular health, and ongoing blood pressure monitoring should be evaluated prior to and during Bioniche Pharma therapy.
ADVERSE REACTIONS & CLINICAL MONITORING
Side effects are predominantly linked to central monoaminergic and sympathomimetic activity associated with Bioniche Pharma administration:
- Common Reactions: Xerostomia (dry mouth), anorexia, insomnia, constipation, and cephalea (headache) reported during Bioniche Pharma treatment.
- Cardiovascular Considerations: Sympathomimetic effects may induce transient elevations in resting heart rate and blood pressure; regular monitoring of cardiovascular parameters is recommended during Bioniche Pharma therapy.
STORAGE & HANDLING
Store Bioniche Pharma products in a cool, dry place away from direct light exposure, elevated ambient temperatures, and humidity. Keep strictly out of reach and sight of children.